Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. - Wikidata - wikimedia - TriplyDB

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.

http://www.wikidata.org/entity/Q44316923

about

Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers Risk factors in coronary atherosclerosis athero-inflammation: the meeting point The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade Serum amyloid A: an acute-phase protein involved in tumour pathogenesis Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats Are thiazolidinediones good or bad for the heart?An M1-like Macrophage Polarization in Decidual Tissue during Spontaneous Preterm Labor That Is Attenuated by Rosiglitazone Treatment.Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients.Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.Peroxisome Proliferator-Activated Receptor Expression in Murine Models and Humans with Age-related Macular Degeneration.Association of SELE genotypes/haplotypes with sE-selectin levels in Taiwanese individuals: interactive effect of MMP9 level.Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.Thiazolidinediones -- some recent developments.Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both.Peroxisome proliferator-activated receptor ligands in atherosclerosis.Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination Decrease in serum matrix metalloproteinase-9 and matrix metalloproteinase-3 levels in Zucker fa/fa obese rats after treatment with swertiamarin Thiazolidinediones and inflammation.Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.Review article: diabetes and atherosclerosis--running on a common road.Therapeutical effects of PPAR agonists assessed by biomarker modulation.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus?The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis PPAR Agonists and Cardiovascular Disease in Diabetes.Peroxisome proliferator-activated receptor and age-related macular degeneration Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients.Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Nuclear receptors in macrophages: a link between metabolism and inflammation.Measuring biomarkers to assess the therapeutic effects of PPAR agonists?

P2860

Q24644869-E8F6B311-91B4-4AE7-A83A-CC4E6496EFDE Q24793107-0C447FC7-3AF1-47FB-A6EE-A45292E0E5BE Q24794673-C14CBFB4-4B7F-4F00-AD1C-3EB40F6BF2CA Q28288148-E0A9EE50-F051-4EA6-B5D3-F1C9E824219B Q28291806-F8A1FA4B-801C-49AA-B0E3-C78F6884B8DC Q28730724-0BEF36B1-5218-45D8-B82D-1D09CC43B209 Q30435005-BEE30486-2D65-4395-97AF-B2EAA60BBADA Q30724406-1D480680-C874-4344-A46F-E901DD840529 Q33686312-2188673B-E0E5-4141-9F72-12609C52F2FD Q33827960-CF36E0B6-69A4-44F7-95B8-4FD563DB14E7 Q34067485-4931A74E-4344-466F-84A9-5A9F54071CB3 Q34386751-8EF11ED0-99FB-4002-B924-A0ED8E693551 Q34494426-85F1F468-EB57-4AC7-A064-7F26C1199879 Q35021504-848246CA-255E-44B0-A086-7DBA507053D5 Q35164761-CB60EC00-B2D9-4075-9236-0E82EA8C99EC Q35672091-1C50F0AF-8906-4340-828E-C893CF863CDB Q35674263-AFE4B941-E1F6-462E-AB5C-C4ADF5CDE492 Q35688221-35D65E84-DD48-4001-B7D2-6DD9C38BF2A6 Q35754155-B2EDCF6D-4B24-4949-AF5A-5E558AE820FA Q35925566-21EAC575-738B-4A34-9E3A-E8BAA6ED5937 Q36013099-5CA96083-4AD3-49D4-A217-D7D76A9F748A Q36058970-8BC094D5-27CA-4F96-964B-7B08AEE48D5C Q36283538-0928475B-D389-41AA-BE06-8AC1ACC1ADA8 Q36283822-46AFA68A-19DF-470E-A24C-FD25E0251D4A Q36286273-74AA993F-B475-4850-8ED3-0978B94B1375 Q36317991-98B2DFE5-8184-42AD-98C0-54045239A8E6 Q36319330-B353AC8B-5130-437C-A3EF-27CC0F3F551D Q36364062-BE5D9109-18C0-4F60-8372-55EA6D7BE65F Q36367490-EB7EC6F4-1E91-4FBB-82BF-5ED7189EE416 Q36390892-E876919B-DA7E-4CB3-BBA9-E989F4B6144A Q36405110-9636E848-65BC-4C73-B821-E8E75DC939F4 Q36444975-1F882F24-C60D-47A1-B9AD-CAAA7C61F72F Q36446030-30E0AADC-19AD-4E20-9B0E-F80823964BB0 Q36591722-497E69A4-E393-491D-A8A1-583503354DF7 Q36768458-1854EEBD-F888-4474-BB2D-233CBD5B795C Q36772880-F7F0E6AB-BB1B-4070-AD66-9BCE2F4095C2 Q36909303-C0294CE8-849D-4948-ADE5-0D47831A7D08 Q36992256-D52A06FA-1E5D-4265-BCC2-A28197AA298D Q37005645-61391721-AA83-49A4-9D3D-66665E9C3E55 Q37012012-86C12EE8-97D0-405C-A22E-E146486DB08E

P2860

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.

http://www.wikidata.org/entity/Q44316923

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@en

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@nl

type

label

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@en

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@nl

prefLabel

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@en

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@nl

P1433

Q44316923-F50839F6-CD87-4331-AB11-93B49AD0A059

P1476

Q44316923-9169F2B3-EB1F-4474-97BF-F5EC68AD05E7

P2093

Q44316923-0E091FDD-06FF-4505-A092-AFB6ADBFA7B2

Q44316923-49C631E3-916D-4E6C-84A0-C2B4471B8148

Q44316923-552211A5-5625-47DA-A3F0-3C0543FC29D9

Q44316923-9011F6A6-2940-422A-BE58-C1F8DB1D182E

Q44316923-DCCA9A2C-9E4B-4086-B4CB-1999E0B16564

Q44316923-E2CB2C41-6673-4962-97B5-58997DCB806E

Q44316923-F548C9A9-B047-49EF-86D3-21CFD9F5016B

P304

Q44316923-3EFC3C3E-65DB-46F6-A52A-C5F875EA3CEA

P31

Q44316923-C8EAFF10-2829-43E7-97AA-A277050AD5A7

P356

Q44316923-28DA8F4F-C504-45BA-9EA9-1770AF1F85AA

P407

Q44316923-35CB860D-3FC8-483F-8EA3-0CE999CCE4AC

P433

Q44316923-316380E1-736C-4B26-BECA-027B2BD0B567

P478

Q44316923-8B240D90-4E2B-4B2D-842E-3F1018987BE4

P50

Q44316923-C8830658-D166-472C-B67C-FF8AF2B8D10A

Q44316923-D7EF3AC7-8A2F-4838-8C15-B2B5EF016614

P577

Q44316923-2C321B67-685A-4A83-B7C0-6B4A2C61BEA9

P698

Q44316923-58B2A844-12D7-453B-969F-E94D25080E7A

P921

Q44316923-6F4CE72D-6D3F-4A01-8D29-4E36B17BA39E

P356

01.ATV.0000054195.35121.5E

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Antidiabetic PPAR gamma-activa ...... with coronary artery disease.

@en

P2093

Arnold Schmidt

http://www.w3.org/2001/XMLSchema#string

Gerhard Wierse

http://www.w3.org/2001/XMLSchema#string

Jochen Ittner

http://www.w3.org/2001/XMLSchema#string

Johannes Froehlich

http://www.w3.org/2001/XMLSchema#string

Laila Siam

http://www.w3.org/2001/XMLSchema#string

Nikolaus Marx

http://www.w3.org/2001/XMLSchema#string

Vinzenz Hombach

http://www.w3.org/2001/XMLSchema#string

P304

283-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.ATV.0000054195.35121.5E

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang Koenig

Hubert Scharnagl

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12588772

http://www.w3.org/2001/XMLSchema#string

P921